Allogene Therapeutics, Inc. (ALLO)
- Previous Close
3.3700 - Open
3.3700 - Bid 3.0000 x 600
- Ask 3.0700 x 400
- Day's Range
3.0300 - 3.4200 - 52 Week Range
2.2300 - 6.8900 - Volume
2,058,203 - Avg. Volume
2,282,691 - Market Cap (intraday)
518.998M - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0900 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.69
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
www.allogene.comRecent News: ALLO
Performance Overview: ALLO
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALLO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALLO
Valuation Measures
Market Cap
519.00M
Enterprise Value
165.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.02k
Price/Book (mrq)
1.01
Enterprise Value/Revenue
1.74k
Enterprise Value/EBITDA
-0.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.84%
Return on Equity (ttm)
-55.51%
Revenue (ttm)
95k
Net Income Avi to Common (ttm)
-327.26M
Diluted EPS (ttm)
-2.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
448.7M
Total Debt/Equity (mrq)
18.57%
Levered Free Cash Flow (ttm)
-134.26M